Abbott Q2 adjusted EPS $1.14, revenue $10.4B; raises FY guidance

ABBOTT LABORATORIES

2024-Q2 EPS reported $1.44 revenue$20,341,000,000

GAAP EPS $0.74, adjusted $1.14; revenue $10.4B (+4% reported, +9.3% organic ex-COVID).
FY2024 guidance raised: GAAP EPS $3.30-$3.40, adjusted $4.61-$4.71; organic sales growth 9.5%-10.0%.
Medical Devices organic growth 12.1%; FreeStyle Libre sales $1.6B (+20.4% organic).
New product approvals: Esprit BTK (FDA), Lingo/Libre Rio (FDA), AVEIR dual-chamber (CE Mark).
Quarterly dividend $0.55 payable Aug 15; 52nd consecutive year of dividend increase.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.